The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. OptimizeRx Corp shares valued at $2,443,761 were purchased by Lang James Paul on Mar 14 ’25. At $7.60 per share, Lang James Paul acquired 321,408 shares. The insider’s holdings grew to 389,452 shares worth approximately $5.1 million following the completion of this transaction.
Also, FEBBO WILLIAM J purchased 20,000 shares, netting a total of over 100,220 in proceeds. Following the buying of shares at $5.01 each, the insider now holds 601,253 shares.
As published in a research note from RBC Capital Mkts on January 08, 2025, OptimizeRx Corp [OPRX] has been rated down from an Outperform to a Sector perform and the price target has been revised to $6 from $7. Analysts at Stephens started covering the stock with ‘”an Equal-weight”‘ outlook in a report released in mid December. Earlier on April 04, 2024, JMP Securities initiated its rating. Their recommendation was “a Mkt outperform” for OPRX stock.
Analyzing OPRX Stock Performance
On last trading session,, OptimizeRx Corp [NASDAQ: OPRX] plunged -2.31% to $13.09. During the last five days, there has been a drop of approximately -13.88%. Over the course of the year, OptimizeRx Corp shares have jumped approximately 169.34%. Shares of the company reached a 52-week high of $15.71 on 06/12/25 and a 52-week low of $3.99 on 03/11/25.
Support And Resistance Levels for OptimizeRx Corp (OPRX)
According to the 24-hour chart, there is a support level at 12.74, which, if violated, would cause prices to drop to 12.39. In the upper region, resistance lies at 13.43. The next price resistance is at 13.77. RSI (Relative Strength Index) is 52.62 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of OptimizeRx Corp (OPRX)?
In terms of OptimizeRx Corp share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 11.94% from the previous closing price of $13.40. Analysts anticipate OptimizeRx Corp stock to reach 15 by 2025, with the lowest price target being 15. In spite of this, 3 analysts ranked OptimizeRx Corp stock as Buy at the end of 2025. On January 03, 2024, Barclays assigned a price target of “an Equal weight” to the stock and initiated coverage with a $15.
